Managing mild autonomous cortisol secretion (MACS): evaluating the role of medical treatment - Report - MDSpire

Managing mild autonomous cortisol secretion (MACS): evaluating the role of medical treatment

  • By

  • Ee Wen Loh

  • Miguel Debono

  • June 30, 2026

  • 0 min

Share

Clinical Report: Evaluating Medical Interventions in the Management of MACS

Background

Mild autonomous cortisol secretion (MACS) is increasingly recognized due to the rising incidence of adrenal incidentalomas, with 20-50% of these patients exhibiting cortisol excess. MACS is associated with significant comorbidities, including diabetes, hypertension, and increased cardiovascular risk.

Data Highlights

No numerical data available.

Key Findings

  • MACS is defined by post-dexamethasone serum cortisol >50nmol/L in the absence of overt Cushing’s syndrome.
  • Adrenalectomy has shown metabolic improvement in patients with MACS, with 46% of surgical patients reducing antihypertensive treatment.
  • Medical treatment with metyrapone effectively lowers nocturnal cortisol levels and improves metabolic risk parameters.
  • Patients with MACS exhibit elevated IL-6 levels, contributing to cardiovascular risk.
  • Current management strategies must consider individual patient factors.

Clinical Implications

Clinicians should evaluate the presence of cortisol-related comorbidities when considering treatment options for MACS.

Conclusion

The management of MACS requires a tailored approach, balancing surgical and medical options.

Related Resources & Content

  1. European Society of Endocrinology clinical practice guidelines, PubMed, 2023 -- Management of adrenal incidentalomas
  2. Mild autonomous cortisol secretion: pathophysiology, comorbidities and management approaches, Nature Reviews Endocrinology, 2023
  3. Surgery for the treatment of arterial hypertension in patients with unilateral adrenal incidentalomas and mild autonomous cortisol secretion (CHIRACIC), ScienceDirect, 2023
  4. Evaluating Cortisol Levels for Diagnosing Adrenal Insufficiency Post-Adrenalectomy in Patients with Mild Autonomous Cortisol Secretion, The Journal of Clinical Endocrinology & Metabolism, 2023
  5. Circadian Patterns of Cortisol Secretion and Steroid Metabolome Analysis in Individuals with Mild Autonomous Cortisol Secretion, The Journal of Clinical Endocrinology & Metabolism, 2023
  6. aace endocrine ai — Predictive Models May Aid MACS Diagnosis
  7. The Journal of Clinical Endocrinology & Metabolism — Surgical Adrenalectomy Lowers Vertebral Fracture Risk in Individuals With Mild Autonomous Cortisol Secretion
  8. Predictive Models May Aid MACS Diagnosis
  9. European Society of Endocrinology clinical practice guidelines on the management of adrenal incidentalomas, in collaboration with the European Network for the Study of Adrenal Tumors - PubMed
  10. Mild autonomous cortisol secretion: pathophysiology, comorbidities and management approaches | Nature Reviews Endocrinology
  11. Comorbidities in mild autonomous cortisol secretion and the effect of treatment: systematic review and meta-analysis | European Journal of Endocrinology | Oxford Academic
  12. Randomized trial studying metabolic outcomes and quality of life after adrenalectomy versus conservative management for mild autonomous cortisol secretion - PubMed
  13. Surgery for the treatment of arterial hypertension in patients with unilateral adrenal incidentalomas and mild autonomous cortisol secretion (CHIRACIC): a multicentre, open-label, superiority randomised controlled trial - ScienceDirect
  14. Evaluating the efficacy of surgical and conservative approaches in mild autonomous cortisol secretion: a meta-analysis - PMC
  15. Increased Risk of Vertebral Fractures in Patients With Mild Autonomous Cortisol Secretion | Endocrine Society
  16. https://academic.oup.com/jes/article/10/6/bvag090/8650808
  17. Effects of short-term metyrapone treatment on glycaemic control in patients with mild autonomous cortisol secretion: a pilot study | Endocrine | Springer Nature Link

Original Source(s)

Managing mild autonomous cortisol secretion (MACS): evaluating the role of medical treatment

  • by Ee Wen Loh, Miguel Debono

  • June 30, 2026

Related Content

Which Exercise Best Lowers Ambulatory BP?

‘Combined training and high-intensity interval training were also associated with reductions in 24-hour ambulatory blood pressure’

Investigational Drug Shows Potentialin Phase 3 Obesity Trial

In a 76-week randomized trial, patients with obesity without diabetes who received survodutide achieved greater weight loss and favorable changes in several metabolic measures compared with those who received placebo.

Higher Steroid Exposure Linked to Systemic Adverse Events in CRSwNP

Higher annual oral corticosteroid exposure was associated with greater odds of systemic adverse events, with avascular bone necrosis and pneumonia showing dose-dependent associations with cumulative dose and osteoporosis associated with longer annual exposure duration.